Our findings suggest that targeting MUC5B in the terminal airways of patients with preclinical stages of interstitial lung disease represents a rational strategy to prevent the progression of preclinical pulmonary fibrosis. The gene discussed is MUC5B; the disease is interstitial lung disease.